trial · primary record
Atezolizumab
Extensive Stage Lung Small Cell Carcinoma
| Phase | Phase 1, Phase 2 |
|---|---|
| Status | RECRUITING |
| Sponsor | Unknown |
| Enrolment | 45 |
| Primary completion | 2029-07-25 |
| Primary endpoint | Progression free survival |
| Registry ID | NCT06287775 |
Provenance
- Source: ClinicalTrials.gov
- Fetched at: 2026-10-29T14:32:50.508Z
- Licence class: attribution-required
- Verdict: primary-source
- Entity id: NCT06287775
This record is rendered from the AEaH spine. If the source is unreachable the page is not generated.
Same entity, elsewhere in the suite
- ATEZOLIZUMAB · approval
- Atezolizumab · compound